(24/7 MARKET NEWS) – Magenta Therapeutics (Nasdaq: MGTA) announced, after yesterday’s market close, that it unveiled updated clinical data from the ongoing MGTA-117 Phase 1/2 dose-escalation clinical trial made in an oral presentation today at the American Society of Hematology 2022 Annual (ASH) Meeting in New Orleans and provided across the portfolio program updates.
Magenta Therapeutics is trading higher in this morning’s premarket, at $1.39, 24 cents higher (+20.87%), on 7 million shares traded.
Its 52-week range is $0.9231 to $5.49. Its next inflection points are $1.82, $1.90 and $2.24.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
